Abstract. Sirtuin 1 (Sirt1), a conserved NAD + dependent deacetylase, is a mediator of life span by calorie restriction. However, Sirt1 may paradoxically increase the risk of cancer. Accordingly, the expression level of Sirt1 is selectively elevated in numerous types of cancer cell; however, the mechanisms underlying the differential regulation remain largely unknown. The present study demonstrated that oncoprotein c-Myc was a direct regulator of Sirt1, which accounts for the upregulation of Sirt1 expression only in the cells without functional p53. In p53 deficient cells, the overexpression of c-Myc increased Sirt1 mRNA and protein expression levels as well as its promoter activity, whereas the inhibitor of c-Myc, 10058-F4, induced decreased Sirt1 basal mRNA and protein expression levels. Deletion/mutation mapping analyses revealed that c-Myc bound to the conserved E-box[-189 to -183 base pair (bp)] of the Sirt1 promoter. In addition, p53 and c-Myc shared at least response element and the presence of p53 may block the binding of c-Myc to the Sirt1 promoter, thus inhibit the c-Myc mediated upregulation of Sirt1 promoter activity. The present study indicated that the expression level of Sirt1 was tightly regulated by oncoprotein c-Myc and tumor suppressor p53, which aids an improved understanding of its expression regulation and tumor promoter role in certain conditions.
Introduction
Sirtuin 1 (Sirt1), a conserved NAD + dependent deacetylase, has been implicated in modulating transcriptional silencing and cell survival, and is known to serve a role in tumorigene sis via deacetylation of important transcriptional factors, including tumor protein p53 (p53) (1), E2F transcription factor 1 (E2F1) (2) and nuclear factor-κB (3) .
Despite the paradoxical role of Sirt1 in tumorigenesis, the expression level of Sirt1 is increased in numerous types of cancer cell. Upregulation of Sirt1 is frequently observed in non-melanoma skin cancers, including actinic keratosis, Bowen's disease, squamous cell carcinoma and basal cell carcinoma (4) . Sirt1 expression level is also significantly increased in poorly differentiated mouse and human prostate cancer (5), acute myeloid leukemia (AML) (6) and lymphoma (7) .
The expression level of Sirt1 is differentially regulated by oncogenes and tumor suppressor genes. p53 has been reported to repress the expression of Sirt1 and its removal by forkhead box O3 activated Sirt1 transcription in PC12 neuronal cancer cells (8, 9) . This model is further supported by studies investigating transformation-associated p53 knockout mice, which expressed constitutively higher Sirt1 mRNA expression levels in numerous tissues (10) .
Of note, hypermethylated in cancer 1 (HIC1), another tumor suppressor that acts as a repressor of Sirt1 expression level, formed a transcriptional repression complex with Sirt1, which induced inhibition of Sirt1 transcription (11) . Sirt1 expression is regulated by the transcriptional factor E2F1, which binds two sites within the Sirt1 promoter. E2F1 is a crucial activator of Sirt1 expression level in response to DNA damage (2) . Of note, the majority of the identified transcriptional factors associated with Sirt1 expression regulation are also subjected to Sirt1 deacetylation and form positive or negative feedback loops to fine-tune cell fate.
c-Myc is another oncogenic transcriptional factor that is deacetylated by Sirt1 (12) . It remains unclear whether c-Myc may be involved in feedback loops of Sirt1 deacetylation. In the present study it was revealed that c-Myc directly binds to the conserved E-box (-189 to 183 bp) of the Sirt1 promoter and induces its transcription in p53 deficient cells. p53 inhibited the c-Myc mediated upregulation of Sirt1 promoter activity by blocking its binding to the Sirt1 promoter. This novel , LU LIU  2* , YONGHONG LEI  3 and PEIFU TANG regulation of Sirt1 identified it as the prototype for a novel class of c-Myc and p53 target genes and aids understanding of its role in certain tumor cells. 
Materials and methods

Constructs and antibodies.
Flag-tagged c-Myc and human influenza hemagglutinin-tagged p53 expression vectors were provided by Wuhan Sanyinh Biotechnology (Wuhan, China).
For the luciferase reporter assay, various length fragments of the Sirt1 promoter, starting from either-2852, -200, or -102 to the transcriptional start site (+1) were amplified from human genomic DNA. The primers used in luciferase reporter generation were as follows: -2852 fragment (E1/2/3), 5'-GAC TCG AGC GTC AGC CAC CGT GCT-3' and 5'-TTG CTA GCT CTT CCA ACT GCC TCT-3'; -200 fragment (E2/3), 5'-TTA AGC TTC CTC CGC CCG CCA CGT-3' and 5'-TCG GTA CCT CTT CCA ACT GCC TCT-3'; -102 fragment, 5'-TTA AGC TTG GGT TTA AAT CTC CCG-3' and 5'-ATG GTA CCT CTT CCA ACT GCC TCT-3'. In the -200 fragment, two putative c-Myc binding sites containing the consensus 'CACGTG' were identified using rVISTA2.0 (https://rvista.dcode.org/). Mutant promoter constructs were obtained by changing each 'CACGTG' sequence within the -200 fragment into 'TTTGGG' and named as E2/mutant (mut) or E3/mut respectively. All amplified promoter fragments were cloned into the pGL3-basic luciferase reporter (Promega Corporation, Madison, WI, USA) within restriction enzyme sites SmaI and HindIII. The scrambled siRNA (control) and siRNAs targeting p53 were purchased from Thermo Fisher Scientific, Inc. Indicated overexpression constructs were generated by amplifying the coding region from cDNA obtained from MEF/3T3 and H1299 cells and sub-cloned into the pEF-HA vector (Addgene, Inc., Cambridge, MA, USA). MEF/3T3 and H1299 cells were transiently transfected with siRNAs targeting p53 using Lipofectamine ® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol.
Anti-c-Myc (N262; dilution, 1:100; cat. no. sc-500771), anti-human Sirt1 (dilution, 1:200; cat. no. sc-15404), anti-p53 (dilution, 1:500; cat. no. sc-126) and anti-GAPDH (dilution, 1:500; cat. no. sc-47724) antibodies were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA).
Luciferase reporter assay. H1299 cells were harvested at 36 h after transfection. Cellular promoter activity was determined using the Dual Luciferase Assay System kit, according to the manufacturer's protocol (Promega Corporation). pRL-CMV renilla luciferase was used as an internal control.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
The expression level of Sirt1 was determined by RT of total RNA followed by qPCR analysis. Total RNA was extracted from K562, 293A and MEF/3T3 cells using an RNA extraction kit (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. A total of 2 µg total RNA was reverse transcribed by extension of oligo dT primers using M-MLV reverse transcriptase (New England Biolabs, Inc., Ipswich, MA, USA), according to the manufacturer's protocol. qPCR was performed on a Bio-Rad IQ5 cycler (Bio-Rad Laboratories, Inc., Hercules, CA, USA) using SYBR-Green Master Mix (Takara Biotechnology, Co., Ltd., Dalian, China). The primers used were as follows: Human sirt1, CAG TGG CTG GAA CAG TGA GA (forward) and TCT GGC ATG TCC CAC TAT CA (reverse); human GAPDH, GAG TCA ACG GAT TTG GTC GT (forward) and GAC AAG CTT CCC GTT CTC AG (reverse); mouse sirt1, GTA AGC GGC TTG AGG G (forward) and TTC GGG CCT CTC CGT A (reverse); mouse GAPDH, CGT CCC GTA GAC AAA ATG GT (forward) and GAA TTT GCC GTG AGT GGA GT (reverse). The program was as follows: 95˚C for 2 min, followed by 30 cycles of denaturation at 95˚C for 5 sec, and annealing/extension temperature (55/68˚C) for 1 min. GAPDH was used as reference gene and the method of 2 -ΔΔCq was applied for quantification (13) .
Chromatin immunoprecipitation (ChIP).
K562 and 293A cells were treated with 1% formaldehyde for 15 min at room temperature. Cross-linked chromatin was sheared by sonication for 5 cycles (30 sec on/30 sec off) at 4˚C to 500-1,000 bp and then used for IP with anti-cMyc antibodies as previously described (dilution, 1:100) or non-immune rabbit immunoglobulin G (dilution, 1:500; cat. no., 2729S; Cell Signaling Technology, Inc., Danvers, MA, USA) as a negative control. Immunoprecipitated complexes were collected by protein A Sepharose beads (Upstate Biotechnology, Inc., Lake Placid, NY, USA). The immunoprecipitated chromatin was amplified by PCR with DNA polymerase (Takara Biotechnology, Co., Ltd.) using primers for the human telomerase reverse transcriptase (hTERT) or Sirt1 promoter. The primers were as follows: hTERT, 5'-AGG CCG GGC TCC CAG TGG ATT C-3' and 5'-CGT GGC CAG CGG CAG CAC CTC-3'; Sirt1 E2/3, 5'-GGA GCG GTA GAC GCA ACA-3' and 5'-CTT CCA ACT GCC TCT CTG G-3'; Sirt1 E1: 5'-AGG CCA AGT CAT TTC CTT CC-3' and 5'-ACC TTT GAC GTG GAG GTT TG-3'. The program was as follows: 95˚C for 5 min, followed by 30 cycles of denaturation at 95˚C for 5 sec, annealing/extension temperature (55/68˚C) for 1 min, and a final extension of 68˚C for 10 min. The resulting PCR products were separated by 2% agarose gel electrophoresis.
DNA mediated precipitation. The DNA-protein complex was cross-linked and chromatin DNA was sheared by sonication as previously described. A total of 4 µg biotinylated double strand oligonucleotide from human Sirt1 promoter 222 (5'-CCC AGG CGG AGC GGT AGA CGC AAC AGC CTC CGC CCG CCA CGT GAC CCG TA-3') or the control 276 (5'-CGC CAC AAA GAG GAA GGG CCG CCG GCC GCC GGG GCC GAG TGC GCT TCC AG-3') were incubated with HeLa cell lysate (Abcam, Cambridge, MA, USA) and 30 µl streptavidin agarose beads (BioVision, Inc., Milpitas, CA, USA) slurry at 4˚C for 2 h with agitation. The streptavidin agarose beads specifically bind to the DNA probe. The mixture was pelleted by centrifugation at 700 x g at 4˚C for 10 min and washed with PBS three times. The bound proteins were analyzed by subsequent western blotting.
Western blotting. Cells were lysed with radioimmunoprecipitation assay buffer which containing a mixture of protease inhibitors (Santa Cruz Biotechnology, Inc. Statistical analysis. All the statistical analyses were performed using SPSS version 17.0 (SPSS, Inc., Chicago, IL, USA). All analyses were repeated three times and the data are expressed as the mean ± standard deviation. The comparison between the two groups was performed using Student's t-test. The comparison between the three groups was based on one-way analysis of variance. When the difference was significant, the SNK-q test method was used to compare between groups. P<0.05 was considered to indicate a statistically significant difference. To further confirm the roles of p53 and c-Myc on Sirt1 expression regulation, c-Myc was overexpressed in p53 wild type and knockout MEF/3T3 cells. In agreement with a previous study (17) , the protein expression level of Sirt1 was markedly increased in p53 knockout MEF/3T3s compared with wild-type MEF/3T3s (Fig. 1B) . As expected, enforced expression of c-Myc significantly upregulated the protein expression level of Sirt1 in p53 -/-MEF/3T3 cells (P<0.05), but had no effects on Sirt1 expression level in wild type MEF/3T3 cells (Fig. 1B) . In addition, c-Myc inhibitor 10058-F4 treatment largely reduced Sirt1 protein expression level in p53 -/-MEF/3T3 and p53 -/-HCT116 cells (P<0.05 and P<0.01 with 25 and 50 µM 10058-F4, respectively, for the two cell lines) but not in p53 +/+ MEF/3T3 and p53 +/+ HCT116 cells (Fig. 1C) . The aforementioned results suggest that c-Myc may function as a positive regulator of Sirt1 expression level, whereas p53 inhibited regulation.
Results
c-Myc upregulates the protein expression level of
c-Myc upregulates the mRNA expression level of Sirt1 in p53 deficient cells.
To further explore the regulatory effect of c-Myc on Sirt1 transcription and the underlying mechanism of p53 involvement in c-Myc upregulation to Sirt1, the change of Sirt1 mRNA expression level was examined upon experimental modulation of c-Myc activity in p53 wild type or deficient cells by qPCR. Overexpression of c-Myc resulted in an increased mRNA expression level of Sirt1 in p53 deficient K562 cells ( Fig. 2A, left panel) . Consistently, 10058-F4 treatment induced downregulation of Sirt1 mRNA expression level in K562 cells (right panel). Conversely, neither overexpression of c-Myc or 10058-F4 treatment altered the mRNA expression level of Sirt1 in 293A cells, which express p53 (Fig. 2B) . Subsequently, the present study detected the mRNA expression level of Sirt1 in primary MEF/3T3 cells from p53 wild type or knockout mice. The mRNA expression level of Sirt1 was significantly elevated in p53 -/-MEF/3T3s and overexpression of c-Myc induced a further increase of Sirt1 mRNA expression level in the absence of p53 (Fig. 2C, left panel) . Furthermore, 10058-F4 impaired the mRNA expression level of Sirt1 in p53 knockout, but not in p53 wild type MEF/3T3 (Fig. 2C, right panel) . The results indicated that p53 may affect the transactivation ability of c-Myc on the Sirt1 promoter.
p53 inhibits the binding of c-Myc on the Sirt1 promoter.
To further elucidate the mechanism underlying p53-mediated inhibition of the transactivation ability of c-Myc on Sirt1, the present study first predicted putative c-Myc binding elements in the human Sirt1 promoter using an online program (rVISTA2.0). A total of three potential c-Myc binding elements, consensus sequence CACGTG, were identified in the human Sirt1 promoter 5'-flanking region, and were named E1, E2 and E3, respectively (Fig. 3A) . However, E1 was not conserved across species when comparing the human with mouse and cow counterparts. In contrast, E2 and E3 are highly conserved among various types of species. The present study hypothesized that E2 and E3, but not E1, were the response elements for c-Myc.
To verify this possibility, the dual luciferase assay was performed to evaluate the activity of truncated deletion constructs of the Sirt1 promoter, -2852, -200 and -102. Truncation of the promoter to -102 significantly decreased the baseline activity of the promoter in the control group compared with the full length Sirt1 promoter (-2852; Fig. 3B ) whereas truncation to -200 did not, indicating that the proximal region of the promoter (-200 to -102) is important for promoter activity. Overexpression of c-Myc significantly upregulated full length and -200 truncated Sirt1 promoter activity up to 2-fold compared with the control (Fig. 3B; P<0.05) ; however, deletion of the proximal region (-200 to -102) abolished c-Myc dependent transactivation (Fig. 3B) . These results suggested that c-Myc transactivates the Sirt1 promoter via E2 or E3 but not E1.
To further define the exact response element of c-Myc on human Sirt1 promoter, E2 or E3 point mutants of the Sirt1 promoter were generated, where the individual c-Myc binding sites were mutated. As presented in Fig. 3C (P<0.05) , the point mutation of E2 markedly reduced the induction of Sirt1 promoter activity by c-Myc compared with the truncated wild-type Sirt1 promoter -200, whereas E3/mut was activated by c-Myc to a similar level compared with the truncated wild-type Sirt1 promoter -200. The results suggested that E2 may be the response element for c-Myc.
Subsequently, the results were confirmed by DNA mediated precipitation assay. Biotinylated double strand oligonucleotide 222 (Sirt1 promoter sequence containing E2) or 276 (50 bp upstream of 222, used as the negative control) were incubated with HeLa nuclear extracts and streptavidin agarose beads slurry and the precipitates were analyzed by western blotting. As presented in Fig. 3D , c-Myc bound to the probe 222 but not 276, whereas the negative control GAPDH did not Of note, the E2 site forms part of the element previously identified to respond to p53 (10) . The overlapping two elements may serve a role in the differential regulatory effects of c-Myc on Sirt1 in the absence or presence of p53. In the present study, c-Myc and p53 expressing plasmids (-200) were co-transfected together with Sirt1 promoter reporter plasmids into p53 deficient H1299 cells. As presented in Fig. 3E , overexpression of p53 decreased the Sirt1 promoter activity and abolished the c-Myc-dependent activation of the promoter, which suggested that c-Myc-dependent upregulation of Sirt1 was inhibited by p53 at the transcriptional level.
Based on the aforementioned results, it was hypothesized that p53 and c-Myc share ≥1 response element on the Sirt1 promoter. The binding of p53 may block the recruitment of c-Myc onto its response element. Therefore, a ChIP assay was performed with K562 and 293A cells. The results revealed that the Sirt1 promoter fragment containing E2 co-precipitated with endogenous c-Myc in p53 deficient K562 cells but not in 293A cells expressing p53 (Fig. 3F) . In agreement with the luciferase assay results, E1 was not present in the DNA precipitate of c-Myc in K562 or 293A cells. The hTERT promoter was amplified as a positive control. Taken together, these results suggested that p53 inhibited the binding of c-Myc on the Sirt1 promoter, thus blocking the upregulation of Sirt1 expression level mediated by c-Myc.
Discussion
Previous studies have revealed that Sirt1 expression is tightly regulated by certain transcriptional factors, including p53, HIC1 and E2F1 (2, 10, 11) . The present study demonstrated that Sirt1 transcription was induced by c-Myc when p53 was deficient. The response element for c-Myc induction was co-located with the p53 binding site of the Sirt1 promoter. Therefore, p53 inhibited the upregulation of Sirt1 expression mediated by c-Myc by blocking the binding of c-Myc on the Sirt1 promoter.
Tumor suppressor p53 serves a critical role in suppression of cell growth and proliferation, whereas the oncoprotein c-Myc conversely regulates p53-associated physiological and pathological processes. It is known that there is a negative association between p53 and c-Myc (18) . However, the precise mechanism underlying the repression of p53 and c-Myc has not been fully understood. Early reports suggested that p53 directly suppressed the transcription of c-Myc (19) , whereas c-Myc inhibited p53 expression level via p19ARF, which forms a feedback loop (20) . Another post-transcriptional mechanism underlying p53 repression of c-Myc involves microRNA (miR) -145 (21). p53 induced miR-145 expression and subsequently repressed c-Myc at the protein level (21) . The results of the present study suggest a new mechanism underlying p53 repression of c-Myc function; p53 and c-Myc compete for binding to the same response element, and inversely regulate the expression level of Sirt1. p53 appears to have a stronger affinity to the binding site since the present study didn't detect the binding of c-Myc on the Sirt1 promoter in p53 expressing cells. It's noteworthy that Sirt1 is not the first target identified to be regulated by p53 and c-Myc in a similar manner. It is reported that optimal induction of cyclinB1 promoter by c-Myc only occurs when p53 is concurrently inactivated (22) .
Deregulation of c-Myc oncogene or loss of p53 activity occurs frequently in certain types of human cancer (23) . The results of the present study suggested that c-Myc overexpression affects the transactivation ability of c-Myc on the Sirt1 promoter in p53 deficient cells, elevating the expression level of Sirt1. The combination of c-Myc overexpression and p53 loss of function may contribute to the elevated expression level of Sirt1 in tumor cells, as cells with high expression levels of Sirt1, including AML, squamous cell carcinoma and diffuse large B-cell lymphoma, demonstrated c-Myc overexpression (24) (25) (26) and p53 loss of function (27) . The regulation of Sirt1 expression level by c-Myc and p53 prompted the present study to consider Sirt1 as a target to mediate the oncogenic function of c-Myc.
Taken together, the results of the present study demonstrated that Sirt1 expression level was directly but conversely regulated by c-Myc and p53. p53 inhibited the activation of the Sirt1 promoter by blocking c-Myc recruitment on the Sirt1 promoter. The present study revealed a novel network that regulates the expression of Sirt1 and further elucidated the counterbalance of a tumor suppressor and promoter.
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